Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
Content archived on 2024-06-25

Antibody Immunotherapy for Malaria

Objective

Malaria kills 2-3 million people each year, 75 percent of which are children. The disease is firmly re-established in at least five Eastern European countries. Economic instability in the region as a consequence of the second gulf war has left associated E U states such as Turkey and Azerbaijan facing major epidemics.

Recent European white papers have highlighted the increasing threat of 'airport malaria' and highlight the impact of global warming on the spread of the mosquito vector to parts of Europe thought free of the disease. Novel therapeutics are urgently required since the parasite is developing resistance to all available drugs.

Although a vaccine against malaria is considered the ultimate goal, its development has been beset with difficulties and t he search for alternative therapies has become of global importance. The success of passive immunization strategies to cure malaria in humans suggests that antibody (Ab) based therapies could be used to treat the disease. Ab plays a crucial role in immunity to malaria.

However Ab effectiveness can be enhanced by genetic modifications that improve on nature. In addition to being novel therapeutics, recombinant Abs will increase our base knowledge of both immune and pathological mechanisms operating during the course of infection.

The AIM programme, based at the University of Nottingham, will therefore take advantage of developments in the field of Ab engineering to develop 4 key programmes of research with the view to manufacturing optimal therapeutic antibodies to treat malaria.

These 4 programmes are:
- Develop Ab-based therapeutics for the treatment of malaria.
- To understand which Ab-receptors (Fc-receptors) are best engaged for optimal killing of malaria parasites.
- To determine the role of breast milk and serum Abs in protecting newborn children from malaria.
- To elucidate the molecular mechanisms for involvement of Ab in placental malaria.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP6-2002-MOBILITY-8
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

EXT - Marie Curie actions-Grants for Excellent Teams

Coordinator

THE UNIVERSITY OF NOTTINGHAM
EU contribution
No data
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0